Meeting Banner
Abstract #4226

Utility of MR-Spectroscopy in Early Drug Discovery: Characterization of Psychiatric Dysfunctions & Psycho-active Drug Effects

Sakthivel Sekar1, Joanes Grandjean 1, Joanne Garnell1, Sankar Seramani1, Marc Ceuster2, Hilde Lavreysen2, and Kishore Bhakoo1

1Singapore Bioimaging Consortium, Singapore, Singapore, 2Neuroscience Therapeutic Area, Janssen Pharmaceuticals R&D, Belgium

MR-Spectroscopy offers a unique potential to characterize underlying neuronal mechanisms of psychiatric dysfunctions and the effects of psychoactive drugs, at a fundamental neuro-metabolite level in-vivo. We studied two preclinical disease models: the chronic mild unpredictable stress (CMUS) model, a putative model for depression, and a sub-chronic memantine (NMDA antagonist) model, a putative model for psychosis using single voxel spectroscopy (SVS). Our results represents metabolic fingerprinting of dysfunctions utilising live metabolic flux profiling; documenting neuro-metabolic effects of novel psycho-active drugs, presenting novel insights in-vivo. Our results and unique approach, exemplifies the potential value of SVS in early stage drug discovery and its potential translation to clinical research.

This abstract and the presentation materials are available to members only; a login is required.

Join Here